leucine has been researched along with Carcinoma, Pancreatic Ductal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, X; Wang, L; Wang, S; Yuan, Y; Zhang, Y; Zhong, J; Zhou, Y | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Fujimoto, M; Gotoh, K; Iwagami, Y; Kobayashi, S; Mori, M; Naka, T; Noda, T; Otsuru, T; Serada, S; Takahashi, T; Wada, H; Yamada, D | 1 |
2 other study(ies) available for leucine and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Biomarkers, Tumor; Body Mass Index; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chromatography, Liquid; Diabetes Mellitus, Type 2; Diagnosis, Differential; Early Detection of Cancer; Feasibility Studies; Female; Humans; Isoleucine; Leucine; Lipid Metabolism; Male; Mass Spectrometry; Metabolic Networks and Pathways; Metabolome; Metabolomics; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Principal Component Analysis; Sensitivity and Specificity; Serologic Tests; Valine | 2017 |
Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2 glycoprotein.
Topics: Cadherins; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Glycoproteins; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Leucine; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta1 | 2019 |